SmartCelleTM – A New Platform for Pan-Ocular Delivery

SmartCelle for Pan-Ocular Delivery

 The small size (30nm)  and neutral charge of SmartCelle micelles enables increased access of TA-A001 and other TALLC drugs to the cornea, the trabecular network, the anterior chamber and the posterior chamber. Passage through  the aqueous channels of the sclera also allows access to the retinal pigment epithelium (RPE) and inner retinal layer.  TA-A001 is not an efflux pump substrate.

Safety and Tolerability

SmartCelle micelles are well tolerated after repeated instillation or intravenous administration at high concentration. Their low molecular weight and biodegradability allows predominantly renal clearance.



Phone: 514 883 3447



TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC to Present at ChinaBio

See our updated presentation describing TA-A001 for neovascular disease, wound healing and new ocular bio-distribution data

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020